ClinVar Miner

Submissions for variant NM_001605.3(AARS1):c.2251A>G (p.Arg751Gly) (rs143370729)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000236870 SCV000292445 uncertain significance not provided 2017-01-30 criteria provided, single submitter clinical testing The R751G variant has been previously reported in two unrelated individuals who was homozygous for the variant (Simons et al., 2015). Functional studies show R751G impaired aminoacylation activity in vitro (Simons et al., 2015). R751G was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, and an external database reports R751G was observed in 1/198 (0.5%) alleles from individuals from a population in the state of Utah. The R751G variant is a non-conservative amino acid substitution that alters a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function.
Invitae RCV000556774 SCV000657669 uncertain significance Charcot-Marie-Tooth disease, type 2 2019-10-07 criteria provided, single submitter clinical testing This sequence change replaces arginine with glycine at codon 751 of the AARS protein (p.Arg751Gly). The arginine residue is highly conserved and there is a moderate physicochemical difference between arginine and glycine. This variant is present in population databases (rs143370729, ExAC 0.009%). This variant has been observed in an individual affected with Charcot-Marie-Tooth disease (PMID: 29653220). This variant has also been reported as compound heterozygous and homozygous in individuals with severe infantile epileptic encephalopathy, peripheral neuropathy, and deficient myelination (PMID: 25817015). ClinVar contains an entry for this variant (Variation ID: 190103). Experimental studies have shown that this missense change impairs the ability of the AARS protein to effectively catalyze aminoacylation (PMID: 25817015). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Molecular Genetics Laboratory,London Health Sciences Centre RCV000999715 SCV001156502 uncertain significance Charcot-Marie-Tooth disease criteria provided, single submitter clinical testing
OMIM RCV000170342 SCV000222750 pathogenic Epileptic encephalopathy, early infantile, 29 2015-04-02 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.